Veno-occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: A clinico-pathological analysis

Pediatr Blood Cancer. 2009 Dec 15;53(7):1211-5. doi: 10.1002/pbc.22202.

Abstract

Background: Vincristine (VCR) and actinomycin D (ACD) form the backbone of chemotherapeutic regimens of Wilms tumor treatment. Veno-occlusive disease (VOD) is a potentially life-threatening complication of ACD.

Objectives: To investigate the incidence of VOD after preoperative chemotherapy and assess the effect of dose and frequency of administrating ACD on the occurrence of VOD.

Methods: A single-center retrospective study of patients where liver biopsies were performed after 4 or 8 weeks of preoperative chemotherapy. Patients had localized or metastatic Wilms tumor and were treated according to SIOP 9, 93-1, or 2001 protocol. A correlation was analyzed between histologically confirmed VOD, laboratory parameters, and mode and frequency of ACD administration. Long-term hepatic toxicity was assessed 5 years after the end of therapy.

Results: Ninety-one patients were included in this analysis. Forty-one patients (45.1%) had histological evidence of VOD. The incidence of histologically proven VOD was significantly correlated with single administration of 45 microg/kg ACD (SIOP 2001 protocol) as compared to repeated dosing of l5 microg/kg (P = 0.003). Fifty-two percent of all patients had mild-to-severe abnormal liver enzymes 5 years after accomplishing therapy.

Conclusion: Despite short-course preoperative chemotherapy regimen, patients are at risk of developing histological VOD. This risk is higher when ACD is administered in a 1-day 45 microg/kg regimen as compared to 3 days l5 microg/kg.

MeSH terms

  • Alanine Transaminase / blood
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Aspartate Aminotransferases / blood
  • Chemotherapy, Adjuvant / adverse effects
  • Child
  • Child, Preschool
  • Dactinomycin / administration & dosage
  • Dactinomycin / adverse effects
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Epirubicin / administration & dosage
  • Epirubicin / adverse effects
  • Female
  • Hepatic Veno-Occlusive Disease / chemically induced*
  • Hepatic Veno-Occlusive Disease / epidemiology
  • Hepatic Veno-Occlusive Disease / pathology
  • Humans
  • Incidence
  • Infant
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / surgery
  • Liver / diagnostic imaging
  • Liver / enzymology
  • Liver / pathology
  • Male
  • Neoadjuvant Therapy / adverse effects*
  • Nephrectomy
  • Postoperative Complications / chemically induced
  • Retrospective Studies
  • Ultrasonography
  • Wilms Tumor / drug therapy*
  • Wilms Tumor / surgery

Substances

  • Dactinomycin
  • Epirubicin
  • Doxorubicin
  • Aspartate Aminotransferases
  • Alanine Transaminase